Introduction
============

Intellectual disability (ID) is a complex and heterogeneous clinical condition that affects 1%--2% of the general population, and can result from genetic or environmental factors, or a combination of both. However, most severe forms of ID have a single genetic basis, ranging from chromosomal alterations to point mutations.[@b1-tacg-11-093]--[@b3-tacg-11-093]

About 700 genes have already been associated with ID;[@b4-tacg-11-093] however, a clear genetic explanation for the phenotype of many patients remains unknown. The implementation of whole exome sequencing (WES) in the last decade increased the identification yield of new mutations and genes associated with various diseases, and led to the demonstration that de novo mutations are a frequent cause of ID.[@b5-tacg-11-093] WES has also successfully identified autosomal recessive[@b6-tacg-11-093],[@b7-tacg-11-093] and X-linked[@b8-tacg-11-093],[@b9-tacg-11-093] causative mutations in ID cohorts.

In non-familial cases, the situation is complicated by the lack of information on the type of inheritance underlying the phenotype. To date, studies of sporadic cases that have been performed using WES to elucidate the causes of ID have led to the diagnosis of 15%--30% of the patients.[@b10-tacg-11-093]--[@b12-tacg-11-093]

Through the exome sequencing of probands and their unaffected parents (trio analysis), this work aimed at identifying variants, which could explain ID in sporadic cases, and evaluating the utility of trio-based exome sequencing in the identification of pathogenic variants.

Patients and methods
====================

The patients were referred to the Genetic Counseling Service of the Department of Genetics and Evolutionary Biology, Institute of Biosciences, University of São Paulo. The study was approved by the Ethics Committee of the institution. Written informed consent was obtained from the parents of all patients.

The patients had ID ranging from moderate to severe and other associated clinical signs. [Table 1](#t1-tacg-11-093){ref-type="table"} summarizes the main clinical findings of the patients in the cohort.

Genomic DNA from peripheral blood samples was extracted, according to standard procedures. Fragile-X syndrome (AmplideX^®^ FMR1; Asuragen, Austin, TX, USA) and genomic imbalances (180K platform; Agilent Technologies, Santa Clara, CA, USA, or 850K platform; Illumina, San Diego, CA, USA) had previously been excluded in these families.

Genomic libraries were constructed using the SureSelect XT or SureSelect QXT kit V6 (Agilent SureSelect Whole Exome Enrichment kit), according to the manufacturer's instructions, with 100× coverage and 90% of the targets covered at 20×; sequencing was performed on the Hiseq 2500 sequencer from Illumina. The quality of the sequencing was verified through the FastQC program (Babraham Institute). The raw reads were aligned to the reference genome (GRCh37/hg19), using the Burrows--Wheeler Aligner,[@b13-tacg-11-093] and pre-processed according to GATK toolkit,[@b14-tacg-11-093] which involves indel realignment, base quality score recalibration, base alignment quality scoring, and variant calling. Filtering and prioritization were conducted using VarSeq® software (Golden Helix, Bozeman, MT, USA) and variant effect predictor. After coding, non-synonymous variants fitting the models of dominant de novo or recessive homozygote/compound heterozygote/hemizygote were filtered per frequency (1%) against the databases: NHLBI ESP6500SI-V2 exomes variant frequencies, ClinVar,[@b15-tacg-11-093] dbSNP138, 1000 Genome Project,[@b16-tacg-11-093] ExAC Browser,[@b17-tacg-11-093] and ABRAOM.[@b18-tacg-11-093]

After variant filtering, in silico prediction of pathogenicity of variants was performed using five prediction algorithms, namely SIFT,[@b19-tacg-11-093] PolyPhen-2,[@b20-tacg-11-093] Mutation Taster,[@b21-tacg-11-093] Mutation Assessor, and FATHMM.[@b22-tacg-11-093] The VarElect online tool was used to prioritize variants according to the phenotype. The OMIM database and scientific literature were used to compare the expected phenotypes with the clinical features of the patients.

Potentially pathogenic variants in the proband were validated by Sanger sequencing also performed to analyze the presence or absence of the same variants in their parents. Variants were classified according to the ACMG guideline.[@b23-tacg-11-093]

Results and discussion
======================

We sequenced the exomes (WES) of eight patients with idiopathic syndromic ID and their parents (trios). Rare variants in eight genes were detected in five patients: a homozygous variant in *ADAMTSL2*; compound heterozygous variants in *NALCN* and *VPS13B*; a variant in the X-linked gene *MID1*; and four heterozygous de novo variants in the autosomal genes *RYR2*, *GABBR2*, *DDX3X*, and *CDK13*. [Table 2](#t2-tacg-11-093){ref-type="table"} summarizes the WES findings; the variants in bold were considered as causative of the clinical phenotypes. The likely pathogenic variants found in this study were missense, except for those in *VPS13B* (stop gain), and the clinical impact could only be estimated, even with the help of prediction algorithms. [Figure 1](#f1-tacg-11-093){ref-type="fig"} illustrates the results, showing the de novo variant detected in *GABBR2* and the maternally inherited variant in *MID1*.

As shown in [Table 2](#t2-tacg-11-093){ref-type="table"}, Patient 1 had rare variants of uncertain significance (VUS) in three different genes:a missense variant in *RYR2*, a gene associated with dominant arrhythmogenic right ventricular dysplasia or ventricular tachycardia, neither of the conditions documented in the patient; a homozygous missense variant in *ADAMTSL2*, whose mutations are known to cause recessive Ehlers--Danlos syndrome, not compatible with the patient's phenotype; and a maternally inherited missense variant in the *MID1* gene, associated with Opitz G/BBB syndrome, which could explain the cognitive impairment, cardiac defects, and cryptorchidism exhibited by the patient. The variant in *MID1* was predicted as damaging (SIFT -- <http://sift.jcvi.org/>) or probably damaging (PolyPhen-2 -- <http://genetics.bwh.harvard.edu/pph2/>), but the *RYR2* variant was also considered probably damaging, and diagnosis of Opitz G/BBB syndrome mostly relied on the fact that the *MID1* variant could explain the phenotype.

Patients 4, 6, and 8 carried de novo variants. The variants in *GABBR2* and in *CDK13* had not been described in the searched databases (GnomAD, dbSNP, and ClinVar) and are therefore novel, while the variant in *DDX3X* had already been described in ClinVar and classified as probably pathogenic.

Patient 4 harbored VUS in *GABBR2*. Variants in this gene have been described recently, and the associated phenotype has not been consolidated in OMIM, but they emerge as important contributors for epileptic encephalopathies,[@b24-tacg-11-093]--[@b27-tacg-11-093] in accordance with our patient clinical phenotype.

Patient 6 carried a known pathogenic variant in *DDX3X*; the disorder associated with this gene, x-linked mental retardation, is clinically variable and includes other symptoms in addition to cognitive impairment, such as hearing loss, which is present in this patient. On the other hand, polycystic kidney disease, exhibited by the patient, has not been reported in *DDX3X* mutation carriers. Although mutations in *DDX3X* have only recently been reported, it is estimated that they are responsible for 1%--3% of idiopathic ID in females.[@b28-tacg-11-093]

Patient 8, carrier of a likely pathogenic variant in *CDK13*, exhibited ID and dysmorphic features commonly associated with *CDK13* mutations, including hypertelorism, telecanthus, inverse epicanthal folds, broad nasal bridge, and low-set, posteriorly rotated ears. She did not present heart defects and seizures, which are frequently found among patients carrying *CDK13* mutations. A recent paper by Hamilton et al shows that mutation in *CDK13* results in syndromic ID, with or without congenital heart disease and seizures.[@b28-tacg-11-093]

In Patient 5, we identified potential pathogenic variants in more than one candidate gene. She was a compound heterozygote for variants in *NALCN*, a gene associated with recessive syndromic hypotonia and psychomotor retardation. This would have been considered as the probable cause of the phenotype if she was not a compound heterozygote for loss of function variants in *VPS13B*, associated with Cohen syndrome. The patient presented many clinical signs of Cohen syndrome in addition to ID, including low birth weight (2300 g), short stature (\<5 centile), microcephaly (\<\<2 centile), palpebral ptosis, myopia, decreased visual acuity, optic atrophy, and neutropenia, but loss of function of both *VPS13B* alleles would have led to Cohen syndrome diagnosis even if phenotypic data were not available. It is disturbing to realize that the *NALCN* variants, which were predicted to be damaging/likely damaging by SIFT and PolyPhen-2, respectively, would likely be considered responsible for the phenotype in the absence of the *VPS13B* variants. However, we cannot exclude the possibility that the *NALCN* variants contribute to the patient's phenotype.

In the last few years, exome sequencing has become an important clinical tool in genetic diagnosis, at least in developed countries. An issue on the procedure is whether only the exome of the proband should be sequenced or sequencing the trio (probands plus parents) would be more cost-effective. Obviously, the latter approach costs three times more, and the magnitude of the increase in diagnostic yield is not clear, depending on the criteria of patient referral. Using the trio analyses of exome sequencing, we identified the probable genetic cause of the clinical phenotype in five out of eight patients with sporadic syndromic ID, which resulted in a diagnostic rate of 62%. It is important to note that some rare variants that were considered as candidate for the phenotypes were later excluded with the release of a database of variants in the Brazilian Population (<http://abraom.ib.usp.br/>), being relatively common variants among Brazilians.[@b18-tacg-11-093]

In the two patients with the diagnosis of recessive disorders, the causative mutations would have been identified even if only the proband exomes had been sequenced. However, in the three patients with dominant disorders, parental exome sequencing was instrumental to reach the conclusion that the de novo variants were likely pathogenic. A recent publication from the Deciphering Developmental Disorders Study on the exomes of 4,293 families reported damaging de novo mutations in 42% of the cohort.[@b29-tacg-11-093] These results clearly show that parental exome sequencing is fundamental for efficient diagnosis in isolated cases.
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![Example of pathogenic mutations identified in the cohort.\
**Notes:** (**A**) Image of the binary alignment map files showing the forward and reverse reads of a segment of the *GABBR2* gene; the mutation from C to T in heterozygosity in the proband, not present in his parents, can be seen in dark blue. Underneath, Sanger sequencing validation of the C/T substitution, (**B**) Image of the BAM files showing the forward and reverse reads of a segment of the *MID1* gene; the mutated allele, in heterozygosity in the mother and hemizygosity in the proband, is seen in dark blue. Underneath, Sanger sequencing validation of the C/T substitution.](tacg-11-093Fig1){#f1-tacg-11-093}

###### 

Main clinical findings of the patients in the cohort

  Patients   Sex      Age (years)   Clinical signs
  ---------- -------- ------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1          Male     5             Intrauterine growth restriction, premature birth, intellectual disability, autistic behavior, cardiac abnormalities (interatrial communication and pulmonary stenosis), cryptorchidism, facial dysmorphisms
  2          Female   11            Intellectual disability, absent speech, seizures, bilateral congenital cataract, hypotonia of upper and lower limbs
  3          Female   6             Intellectual disability, hypotonia, high-arched palate, facial dysmorphisms, renal and cardiac malformations
  4          Male     11            Intellectual disability, absent speech, no ambulation, epileptic encephalopathy
  5          Female   5             Intellectual disability, short stature, microcephaly, palpebral ptosis, myopia, decreased visual acuity, optic atrophy, neutropenia
  6          Female   23            Intellectual disability, absent speech, bilateral hearing loss, facial dysmorphisms, arachnoid cyst, bilateral preauricular appendages, polycystic kidney disease
  7          Male     17            Intellectual disability, short stature, and myotonia
  8          Female   6             Intellectual disability, poor speech, facial dysmorphisms

###### 

The candidate mutations identified in five of the patients of the cohort

  Patients   Gene           Variation (ref/Alt)   Position          Exon     Inheritance pattern   Family segregation                                Amino acid exchange   OMIM phenotype   Effect                Gnomad       dbSNP             ClinVar
  ---------- -------------- --------------------- ----------------- -------- --------------------- ------------------------------------------------- --------------------- ---------------- --------------------- ------------ ----------------- -----------------------------------------------
  1          *RYR2*         G/A                   1:237957254       95       Dominant              Heterozygous, de novo                             p.Asp4624Asn          600996, 604772   Missense              --           --                --
             ***MID1***     **C/T**               **X:10535359**    **2**    **X-linked**          **Inherited from the mother, hemizygous**         **p.Val77Ile**        **300000**       **Missense**          **0.0001**   **rs143416243**   --
             *ADAMTSL2*     G/A                   9:136419629       10       Recessive             Homozygous, inherited from heterozygous parents   p.Val364Ile           231050           Missense              --           rs35767802        --
  **4**      ***GABBR2***   **C/T**               **9:101133817**   **12**   **Dominant**          **Heterozygous, de novo**                         **p.Ala567Thr**       --               **Missense**          --           --                --
  5          *NALCN*        C/T                   13:101717778      40       Recessive             Heterozygous, inherited from the father           p.Val1528Ile          615419           Missense              0.0122       rs767980482       --
             *NALCN*        C/A                   13:101721179      38       Recessive             Heterozygous, inherited from the mother           p.Val1400Phe          615419           Missense              0.0186       rs771656968       --
             ***VPS13B***   **C/T**               **8:100654570**   **34**   **Recessive**         **Heterozygous, inherited from the father**       **p.Arg1943\***       **216550**       **LoF (stop gain)**   **0.0323**   **rs386834099**   **Pathogenic/likely pathogenic RCV000050092**
             ***VPS13B***   **C/G**               **8:100865871**   **56**   **Recessive**         **Heterozygous, inherited from the mother**       **p.Tyr3443\***       **216550**       **LoF (stop gain)**   --           --                --
  **6**      ***DDX3X***    **T/C**               **X:41206163**    **15**   **X-linked**          **Heterozygous, de novo**                         **p.Leu556Ser**       **300958**       **Missense**          --           --                **Likely pathogenic RCV000424111**
  **8**      ***CDK13***    **G/C**               **7:40087439**    **7**    **Dominant**          **Heterozygous, de novo**                         **p.Asp855His**       --               **Missense**          --           --                --

**Note:** Variants in bold are considered to be causative of the phenotypes.

**Abbreviations:** Alt, alternate nucleotide; LoF, loss of function; OMIM, Online Mendelian Inheritance in Man; Ref, reference nucleotide.
